Nanjing University School Of Medicine
Clinical trials sponsored by Nanjing University School Of Medicine, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take aim at autoimmune kidney diseases Results expected Dec 2026 (estimated)
- Could biologic drugs offer a better way to treat lupus kidney disease? Results expected Jun 2027 (estimated)
-
Engineered immune cells take aim at autoimmune kidney diseases
Disease control Recruiting nowThis early-stage trial tests a new therapy called FKC289, which uses a patient's own immune cells engineered to target two proteins (BCMA and CD19) on cells that drive autoimmune attacks. The goal is to see if it is safe and can help control kidney diseases like lupus nephritis a…
Phase 1 • Sponsor: Nanjing University School of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could biologic drugs offer a better way to treat lupus kidney disease?
Disease control Recruiting nowThis phase 2 trial is testing whether biologic drugs (belimumab or telitacicept) can improve kidney outcomes in people with active lupus nephritis better than standard therapy. About 50 participants will be randomly assigned to one of three treatment groups for six months. The go…
Phase 2 • Sponsor: Nanjing University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC